Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Finished Goods (2016 - 2017)

Integra Lifesciences Holdings (IART) has disclosed Finished Goods for 7 consecutive years, with $136.7 million as the latest value for Q3 2017.

  • Quarterly Finished Goods changed N/A to $136.7 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $136.7 million through Sep 2017, changed N/A year-over-year, with the annual reading at $128.0 million for FY2016, N/A changed from the prior year.
  • Finished Goods hit $136.7 million in Q3 2017 for Integra Lifesciences Holdings, up from $128.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $150.5 million in Q4 2014 to a low of $128.0 million in Q4 2016.
  • Historically, Finished Goods has averaged $140.5 million across 4 years, with a median of $141.8 million in 2015.